Acarbose
Tranylcypromine may increase the hypoglycemic activities of Acarbose.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Tranylcypromine.
Aldesleukin
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aldesleukin.
Advertisement
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.
Altretamine
Altretamine may increase the orthostatic hypotensive activities of Tranylcypromine.
Amiloride
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amiloride.
Advertisement
Amitriptyline
Tranylcypromine may increase the serotonergic activities of Amitriptyline.
Amlodipine
Tranylcypromine may increase the hypotensive activities of Amlodipine.
Amoxapine
Tranylcypromine may increase the serotonergic activities of Amoxapine.
Advertisement
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Tranylcypromine.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranylcypromine.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranylcypromine.
Amprenavir
The metabolism of Amprenavir can be decreased when combined with Tranylcypromine.
Amsacrine
The metabolism of Amsacrine can be decreased when combined with Tranylcypromine.
Aprepitant
The metabolism of Aprepitant can be decreased when combined with Tranylcypromine.
Astemizole
The metabolism of Astemizole can be decreased when combined with Tranylcypromine.
Atenolol
Tranylcypromine may increase the hypotensive activities of Atenolol.
Atomoxetine
Tranylcypromine may increase the central neurotoxic activities of Atomoxetine.
Atropine
Tranylcypromine may increase the hypertensive activities of Atropine.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Tranylcypromine.
Benazepril
Tranylcypromine may increase the hypotensive activities of Benazepril.
Bendroflumethiazide
Tranylcypromine may increase the hypotensive activities of Bendroflumethiazide.
Benztropine
The metabolism of Benzatropine can be decreased when combined with Tranylcypromine.
Betaxolol
The metabolism of Betaxolol can be decreased when combined with Tranylcypromine.
Bethanidine
Tranylcypromine may increase the hypotensive activities of Bethanidine.
Bisoprolol
The metabolism of Bisoprolol can be decreased when combined with Tranylcypromine.
Bortezomib
The metabolism of Bortezomib can be decreased when combined with Tranylcypromine.
Bosentan
Tranylcypromine may increase the hypotensive activities of Bosentan.
Bosentan Anhydrous
Tranylcypromine may increase the hypotensive activities of Bosentan.
Brimonidine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.
Buspirone
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Buspirone.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Tranylcypromine.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Tranylcypromine.
Caffeine
The metabolism of Caffeine can be decreased when combined with Tranylcypromine.
Carbamazepine
The risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.
Carisoprodol
The metabolism of Carisoprodol can be decreased when combined with Tranylcypromine.
Carteolol
The metabolism of Carteolol can be decreased when combined with Tranylcypromine.
Cephalexin
The metabolism of Cephalexin can be decreased when combined with Tranylcypromine.
CEPHALEXIN ANHYDROUS
The metabolism of Cephalexin can be decreased when combined with Tranylcypromine.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Tranylcypromine.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Tranylcypromine.
Cevimeline
The metabolism of Cevimeline can be decreased when combined with Tranylcypromine.
Chloramphenicol
The metabolism of Chloramphenicol can be decreased when combined with Tranylcypromine.
Chlordiazepoxide
The metabolism of Chlordiazepoxide can be decreased when combined with Tranylcypromine.
Chloroquine
The metabolism of Chloroquine can be decreased when combined with Tranylcypromine.
Chlorpromazine
The metabolism of Chlorpromazine can be decreased when combined with Tranylcypromine.
Chlorpropamide
The metabolism of Chlorpropamide can be decreased when combined with Tranylcypromine.
Chlorthalidone
Tranylcypromine may increase the hypotensive activities of Chlorthalidone.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Tranylcypromine.
Cisapride
The metabolism of Cisapride can be decreased when combined with Tranylcypromine.
Citalopram
The serum concentration of Citalopram can be increased when it is combined with Tranylcypromine.
Clemastine
Tranylcypromine may increase the anticholinergic activities of Clemastine.
Clobazam
The metabolism of Clobazam can be decreased when combined with Tranylcypromine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Tranylcypromine.
Clonidine
Tranylcypromine may increase the hypertensive activities of Clonidine.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.
Clozapine
The metabolism of Clozapine can be decreased when combined with Tranylcypromine.
Codeine
The therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.
Codeine Anhydrous
The therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.
CODEINE POLISTIREX
The therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.
Cyclophosphamide Anhydrous
The metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.
Cyclothiazide
Tranylcypromine may increase the hypotensive activities of Cyclothiazide.
Cyproheptadine
Tranylcypromine may increase the anticholinergic activities of Cyproheptadine.
Dapiprazole
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Tranylcypromine.
Dapsone
The metabolism of Dapsone can be decreased when combined with Tranylcypromine.
Darifenacin
The metabolism of Darifenacin can be decreased when combined with Tranylcypromine.
Delavirdine
The metabolism of Delavirdine can be decreased when combined with Tranylcypromine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine.
Dextromethorphan
Tranylcypromine may increase the serotonergic activities of Dextromethorphan.
Dibucaine
The risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.
Diclofenac
The metabolism of Diclofenac can be decreased when combined with Tranylcypromine.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tranylcypromine.
Diltiazem
The metabolism of Diltiazem can be decreased when combined with Tranylcypromine.
Dipivefrin
Tranylcypromine may increase the hypertensive activities of Dipivefrin.
Disopyramide
Tranylcypromine may increase the hypoglycemic activities of Disopyramide.
Doxapram
Tranylcypromine may increase the hypertensive activities of Doxapram.
Doxazosin
The metabolism of Doxazosin can be decreased when combined with Tranylcypromine.
Doxylamine
Tranylcypromine may increase the anticholinergic activities of Doxylamine.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
Duloxetine
Tranylcypromine may increase the orthostatic hypotensive activities of Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Tranylcypromine.
Eletriptan
The serum concentration of Eletriptan can be increased when it is combined with Tranylcypromine.
Enalapril
Tranylcypromine may increase the hypotensive activities of Enalapril.
Enflurane
The risk or severity of adverse effects can be increased when Enflurane is combined with Tranylcypromine.
Enfuvirtide
The metabolism of Enfuvirtide can be decreased when combined with Tranylcypromine.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.
Epinephrine
Tranylcypromine may increase the hypertensive activities of Epinephrine.
Eplerenone
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eplerenone.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Tranylcypromine.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Tranylcypromine.
Esmolol
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Esmolol.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tranylcypromine.
Etomidate
The risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.
Fenfluramine
Tranylcypromine may increase the serotonergic activities of Fenfluramine.
Fluoxetine
The risk or severity of adverse effects can be increased when Fluoxetine is combined with Tranylcypromine.
Fluphenazine
The metabolism of Fluphenazine can be decreased when combined with Tranylcypromine.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.
Flutamide
The metabolism of Flutamide can be decreased when combined with Tranylcypromine.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tranylcypromine.
Fluvoxamine
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tranylcypromine.
Fosinopril
Tranylcypromine may increase the hypotensive activities of Fosinopril.
Furazolidone
Tranylcypromine may increase the hypertensive activities of Furazolidone.
Furosemide
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Furosemide.
Galantamine
The metabolism of Galantamine can be decreased when combined with Tranylcypromine.
Gefitinib
The metabolism of Gefitinib can be decreased when combined with Tranylcypromine.
Glimepiride
Tranylcypromine may increase the hypoglycemic activities of Glimepiride.
Guanabenz
Tranylcypromine may increase the hypotensive activities of Guanabenz.
Guanadrel
Tranylcypromine may increase the hypotensive activities of Guanadrel.
Haloperidol
The metabolism of Haloperidol can be decreased when combined with Tranylcypromine.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tranylcypromine.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
Imatinib
The metabolism of Imatinib can be decreased when combined with Tranylcypromine.
Imipramine
Tranylcypromine may increase the serotonergic activities of Imipramine.
Indomethacin
The metabolism of Indomethacin can be decreased when combined with Tranylcypromine.
Insulin Glargine
Tranylcypromine may increase the hypoglycemic activities of Insulin Glargine.
insulin human, rDNA origin
Tranylcypromine may increase the hypoglycemic activities of Insulin Human.
Insulin Lispro
Tranylcypromine may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Protamine Lispro, Human
Tranylcypromine may increase the hypoglycemic activities of Insulin Lispro.
Ipratropium
The metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.
Ipratropium cation
The metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.
Isoetharine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoetarine.
Isradipine
Tranylcypromine may increase the hypotensive activities of Isradipine.
Labetalol
The metabolism of Labetalol can be decreased when combined with Tranylcypromine.
Lamotrigine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lamotrigine.
Lansoprazole
The metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.
Latanoprost
Tranylcypromine may increase the hypotensive activities of Latanoprost.
Lercanidipine
Tranylcypromine may increase the hypotensive activities of Lercanidipine.
Lidocaine
The metabolism of Lidocaine can be decreased when combined with Tranylcypromine.
Linezolid
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Linezolid.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Tranylcypromine.
Loratadine
The metabolism of Loratadine can be decreased when combined with Tranylcypromine.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.
Losartan
Tranylcypromine may increase the hypotensive activities of Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Tranylcypromine.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Tranylcypromine.
Magnesium Sulfate
The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Magnesium sulfate.
Mecamylamine
Tranylcypromine may increase the hypotensive activities of Mecamylamine.
Meperidine
Tranylcypromine may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Tranylcypromine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.
Metaraminol
Tranylcypromine may increase the hypertensive activities of Metaraminol.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Tranylcypromine.
Metformin
Tranylcypromine may increase the hypoglycemic activities of Metformin.
Methadone
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadone.
Methazolamide
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methazolamide.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Tranylcypromine.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Tranylcypromine.
Methyclothiazide
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyclothiazide.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tranylcypromine.
Methylphenidate
Tranylcypromine may increase the hypertensive activities of Methylphenidate.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Tranylcypromine.
Metolazone
Tranylcypromine may increase the hypotensive activities of Metolazone.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Tranylcypromine.
Mexiletine
The metabolism of Mexiletine can be decreased when combined with Tranylcypromine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.
Midodrine
Tranylcypromine may increase the hypertensive activities of Midodrine.
Miglitol
Tranylcypromine may increase the hypoglycemic activities of Miglitol.
Minoxidil
Tranylcypromine may increase the hypotensive activities of Minoxidil.
Mirtazapine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mirtazapine.
Moexipril
Tranylcypromine may increase the hypotensive activities of Moexipril.
Morphine
The therapeutic efficacy of Morphine can be increased when used in combination with Tranylcypromine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
Nelfinavir
The metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.
Nevirapine
The metabolism of Nevirapine can be decreased when combined with Tranylcypromine.
Nicardipine
The metabolism of Nicardipine can be decreased when combined with Tranylcypromine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Tranylcypromine.
Nicotine
The metabolism of Nicotine can be decreased when combined with Tranylcypromine.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Tranylcypromine.
Nilutamide
The metabolism of Nilutamide can be decreased when combined with Tranylcypromine.
Nimodipine
Tranylcypromine may increase the hypotensive activities of Nimodipine.
Nisoldipine
Tranylcypromine may increase the hypotensive activities of Nisoldipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tranylcypromine.
Nitrofurazone
The metabolism of Nitrofural can be decreased when combined with Tranylcypromine.
Nitroprusside
Tranylcypromine may increase the hypotensive activities of Nitroprusside.
Norepinephrine
Tranylcypromine may increase the hypertensive activities of Norepinephrine.
Nortriptyline
Tranylcypromine may increase the serotonergic activities of Nortriptyline.
Olanzapine
Tranylcypromine may increase the serotonergic activities of Olanzapine.
Olmesartan
Tranylcypromine may increase the hypotensive activities of Olmesartan.
Omeprazole
The metabolism of Omeprazole can be decreased when combined with Tranylcypromine.
Oxiconazole
The metabolism of Oxiconazole can be decreased when combined with Tranylcypromine.
Oxycodone
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxycodone.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Tranylcypromine.
Pantoprazole
The metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.
Paregoric
The therapeutic efficacy of Morphine can be increased when used in combination with Tranylcypromine.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.
Pentobarbital
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tranylcypromine.
Phentermine
Tranylcypromine may increase the hypertensive activities of Phentermine.
PHENTERMINE RESIN
Tranylcypromine may increase the hypertensive activities of Phentermine.
Phentolamine
Tranylcypromine may increase the hypotensive activities of Phentolamine.
Phentolamine Mesylate
Tranylcypromine may increase the hypotensive activities of Phentolamine.
Phenylephrine
Tranylcypromine may increase the hypertensive activities of Phenylephrine.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenylpropanolamine.
Phenytoin
The metabolism of Phenytoin can be decreased when combined with Tranylcypromine.
Piperazine
The metabolism of Piperazine can be decreased when combined with Tranylcypromine.
Pramipexole
Tranylcypromine may increase the sedative activities of Pramipexole.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Tranylcypromine.
Prazosin
Tranylcypromine may increase the hypotensive activities of Prazosin.
Pregabalin
The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Pregabalin.
Prochlorperazine
The metabolism of Prochlorperazine can be decreased when combined with Tranylcypromine.
Progesterone
The metabolism of Progesterone can be decreased when combined with Tranylcypromine.
Promazine
The risk or severity of adverse effects can be increased when Promazine is combined with Tranylcypromine.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.
Propranolol
The metabolism of Propranolol can be decreased when combined with Tranylcypromine.
Protriptyline
Tranylcypromine may increase the serotonergic activities of Protriptyline.
Quinine
The metabolism of Quinine can be decreased when combined with Tranylcypromine.
Ramipril
Tranylcypromine may increase the hypotensive activities of Ramipril.
Regular Insulin, Human
Tranylcypromine may increase the hypoglycemic activities of Insulin Human.
Remoxipride
The metabolism of Remoxipride can be decreased when combined with Tranylcypromine.
Reserpine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.
Ritonavir
The metabolism of Ritonavir can be decreased when combined with Tranylcypromine.
Ropinirole
Tranylcypromine may increase the sedative activities of Ropinirole.
Ropivacaine
The metabolism of Ropivacaine can be decreased when combined with Tranylcypromine.
Rosiglitazone
Tranylcypromine may increase the hypoglycemic activities of Rosiglitazone.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.
Sildenafil
The metabolism of Sildenafil can be decreased when combined with Tranylcypromine.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Tranylcypromine.
Sotalol
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sotalol.
Spironolactone
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Spironolactone.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Tranylcypromine.
Sulfadiazine
Tranylcypromine may increase the hypoglycemic activities of Sulfadiazine.
Sulfisoxazole
Tranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Sulpiride is combined with Tranylcypromine.
Sumatriptan
The serum concentration of Sumatriptan can be increased when it is combined with Tranylcypromine.
Sumatriptan Succinate
The serum concentration of Sumatriptan can be increased when it is combined with Tranylcypromine.
Tamoxifen
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.
Teniposide
The metabolism of Teniposide can be decreased when combined with Tranylcypromine.
Terfenadine
The metabolism of Terfenadine can be decreased when combined with Tranylcypromine.
Testosterone
The metabolism of Testosterone can be decreased when combined with Tranylcypromine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
Theophylline
The metabolism of Theophylline can be decreased when combined with Tranylcypromine.
Theophylline anhydrous
The metabolism of Theophylline can be decreased when combined with Tranylcypromine.
Thiopental
The risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.
Ticlopidine
The metabolism of Ticlopidine can be decreased when combined with Tranylcypromine.
Timolol
The metabolism of Timolol can be decreased when combined with Tranylcypromine.
Timolol Anhydrous
The metabolism of Timolol can be decreased when combined with Tranylcypromine.
Tizanidine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Tranylcypromine.
Topiramate
The risk or severity of adverse effects can be increased when Topiramate is combined with Tranylcypromine.
Torsemide
Tranylcypromine may increase the hypotensive activities of Torasemide.
Tramadol
Tramadol may increase the neuroexcitatory activities of Tranylcypromine.
Trandolapril
Tranylcypromine may increase the hypotensive activities of Trandolapril.
Travoprost
Tranylcypromine may increase the hypotensive activities of Travoprost.
Trazodone
Tranylcypromine may increase the serotonergic activities of Trazodone.
Treprostinil
Tranylcypromine may increase the hypotensive activities of Treprostinil.
Triamterene
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triamterene.
Triflupromazine
The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tranylcypromine.
Trimethadione
The metabolism of Trimethadione can be decreased when combined with Tranylcypromine.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Tranylcypromine.
Troglitazone
The metabolism of Troglitazone can be decreased when combined with Tranylcypromine.
Tryptophan
The risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tranylcypromine.
Valproate
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Tranylcypromine.
Valproic Acid
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Tranylcypromine.
Valsartan
Tranylcypromine may increase the hypotensive activities of Valsartan.
Venlafaxine
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tranylcypromine.
Verapamil
The metabolism of Verapamil can be decreased when combined with Tranylcypromine.
Vinblastine
The metabolism of Vinblastine can be decreased when combined with Tranylcypromine.
Vinorelbine
The metabolism of Vinorelbine can be decreased when combined with Tranylcypromine.
Voriconazole
The metabolism of Voriconazole can be decreased when combined with Tranylcypromine.
Warfarin
The metabolism of Warfarin can be decreased when combined with Tranylcypromine.
Zidovudine
The metabolism of Zidovudine can be decreased when combined with Tranylcypromine.
Ziprasidone
The metabolism of Ziprasidone can be decreased when combined with Tranylcypromine.
Zolmitriptan
The serum concentration of Zolmitriptan can be increased when it is combined with Tranylcypromine.
Zolpidem
Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
